Silence Therapeutics Could Rival Amgen And Novartis With siRNA Therapy

Early Results Attract Big Pharma Interest

 
• By Andrew McConaghie
  
Cardiovascular
SLN360 is one of a wave of new RNA-based therapies targeting lipoprotein(a) (Lp(a) . • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D